L. Lacroix

D. Planchard, C. Caramella, L. Lacroix, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

A. Geraud, D. Planchard, J. Delahousse, 2020, Cancers.

Phase I / II study of neoadjuvant bevacizumab , erlotinib and 5-fl uorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

I. Bièche, J. Solassol, H. Blons, 2013 .

Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients

S. Filetti, J. Bidart, D. Russo, 2007, Nature Clinical Practice Endocrinology &Metabolism.

Expression of reduced nicotinamide adenine dinucleotide phosphate oxidase (ThoX, LNOX, Duox) genes and proteins in human thyroid tissues.

J. Bidart, B. Caillou, M. Schlumberger, 2001, The Journal of clinical endocrinology and metabolism.

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management

J. Blay, F. Collin, R. Sciot, 2010, British Journal of Cancer.

Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials.

J. Soria, L. Lacroix, A. Hollebecque, 2022, European journal of cancer.

Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice

Xiao-Jun Ma, J. Scoazec, P. Vielh, 2015, Modern Pathology.

Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening

F. André, E. Ruíz-García, J. Bidart, 2010, British Journal of Cancer.

Portrait of Ependymoma Recurrence in Children: Biomarkers of Tumor Progression Identified by Dual-Color Microarray-Based Gene Expression Analysis

P. Varlet, S. Puget, F. Andreiuolo, 2010, PloS one.

Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas

P. Vielh, L. Lacroix, A. Aupérin, 2014, Head & neck.

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project—Part 2)

J. Pignon, B. Chetaille, J. Solassol, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.

I. Bièche, P. Lamy, P. de Cremoux, 2018, Anticancer research.

Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.

D. Planchard, L. Lacroix, B. Besse, 2022, Clinical lung cancer.

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

T. Gorlia, A. Dingemans, E. Felip, 2022, Scientific Reports.

Abstract 3192: Liquid biopsies for molecular profiling of mutations in non-small cell lung cancer patients lacking tissue samples

N. Rosenfeld, D. Planchard, V. Plagnol, 2016 .

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

A. Iafrate, A. Bardia, F. André, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

T. de Baère, F. André, G. Vassal, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System

R. Lotan, W. Hong, I. Wistuba, 2009, Cancer Prevention Research.

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research.

M. Ladanyi, A. Drilon, J. Reis-Filho, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Redifferentiation of a BRAFK601E-Mutated Poorly Differentiated Thyroid Cancer Patient with Dabrafenib and Trametinib Treatment.

E. Baudin, M. Schlumberger, L. Lacroix, 2019, Thyroid : official journal of the American Thyroid Association.

Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.

V. Lazar, S. Filetti, J. Bidart, 1999, The Journal of clinical endocrinology and metabolism.

Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer

I. Bièche, J. Solassol, H. Blons, 2013 .

Response of ovarian carcinomas to gefitinib–carboplatin–paclitaxel combination is not associated with EGFR kinase domain somatic mutations

J. Soria, J. Bidart, L. Lacroix, 2006, International journal of cancer.

Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer.

M. Mathieu, F. André, B. Job, 2012, European journal of cancer.

Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines

G. Kroemer, I. Vitale, P. Dessen, 2009, Oncogene.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

T. de Baère, M. Ducreux, S. Michiels, 2017, European journal of cancer.

Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial—Interim results.

A. Eggermont, T. Baère, F. André, 2013 .

Thymic carcinomas: clinicopathologic study of 37 cases from a single institution

P. Dartevelle, E. Fadel, M. Ghigna, 2013, Virchows Archiv.

Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors

P. Chanson, M. Ducreux, E. Baudin, 2009, International journal of cancer.

Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01).

T. de Baère, F. André, G. Vassal, 2016, European Journal of Cancer.

Endobronchial ultrasound-guided fine-needle aspiration for pulmonary carcinomas genotyping: experience with 398 cases including rapid EGFR/KRAS analysis in 43 cases.

E. Fadel, J. Adam, M. Ghigna, 2018, Journal of Thoracic Disease.

Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B‐cell lymphoma: Results of LNH‐EP1 study

J. Soria, L. Lacroix, J. Rossignol, 2021, American journal of hematology.

L. Zitvogel, N. Chaput, J. Adam, 2022, Journal of experimental & clinical cancer research : CR.

Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial

P. Varlet, S. Michiels, S. Puget, 2017, Clinical Cancer Research.

Changes in Signaling Pathways Induced by Vandetanib in a Human Medullary Thyroid Carcinoma Model , as Analyzed by Reverse Phase Protein Array

S. Broutin, A. Ryan, J. Bidart, 2014 .

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma

T. Baère, V. Lazar, J. Soria, 2013, Investigational New Drugs.

Concordance between HER‐2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients

M. Mathieu, S. Michiels, S. Delaloge, 2016, Molecular oncology.

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

T. de Baère, V. Lazar, J. Soria, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients

F. Ginhoux, E. Solary, D. Drubay, 2022, eBioMedicine.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

D. Mallardo, P. Ascierto, E. Simeone, 2020, Nature Communications.

Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-Hydroxyphenyl)retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells

R. Lotan, D. Lotan, L. Lacroix, 2007, Cancer biology & therapy.

Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.

S. Broutin, J. Bidart, B. Caillou, 2009, Endocrine-related cancer.

18Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging?

F. Bidault, E. Baudin, M. Schlumberger, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Intracellular expression of reactive oxygen species-generating NADPH oxidase NOX4 in normal and cancer thyroid tissues.

J. Bidart, B. Caillou, M. Schlumberger, 2010, Endocrine-related cancer.

Molecular screening for cancer treatment optimization: MOSCATO 01 - A prospective molecular triage trial, interim results

A. Eggermont, T. Baère, F. André, 2013 .

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test

A. Italiano, L. Lacroix, B. Besse, 2022, Cells.

Abstract GS1-10: Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST

I. Bièche, I. Soubeyran, F. André, 2022, Cancer Research.

Genomics to select treatment for patients with metastatic breast cancer

P. Gestraud, S. Boyault, I. Bièche, 2022, Nature.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica

C. Sternberg, M. Ducreux, J. Adam, 2018, Tumori.

Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay.

D. Planchard, V. Plagnol, P. Saintigny, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Sodium/iodide symporter (NIS) gene expression is the limiting step for the onset of thyroid function in the human fetus.

M. Polak, S. Michiels, J. Bidart, 2007, The Journal of clinical endocrinology and metabolism.

Medullary thyroid carcinoma arises in the absence of prolactin signaling.

P. Kelly, B. Caillou, L. Lacroix, 2005, Cancer research.

Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology.

D. Planchard, A. Italiano, J. Soria, 2022, JCO precision oncology.

Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases

D. Planchard, J. Adam, C. Caramella, 2019, Journal of Thoracic Oncology.

The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

N. André, O. Delattre, S. Michiels, 2022, Cancer discovery.

Liquid versus tissue biopsy for detecting actionable alterations according to ESCAT in patients with advanced cancer: A study from the French National Center for Precision Medicine (PRISM).

I. Soubeyran, L. Cerbone, F. Barlesi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal Cancer

Philippe Dessen, Hany Soliman, Peggy Dartigues, 2012, Clinical Cancer Research.

Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1

A. Eggermont, J. Soria, C. Robert, 2011, Clinical Cancer Research.

Radiation exposure and thyroid cancer: a review

M. Schlumberger, S. Chevillard, L. Lacroix, 2017, Archives of endocrinology and metabolism.

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

M. Thomas, C. Robert, L. Lacroix, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Implications of personalized medicine—perspective from a cancer center

Fabrice Andre, F. André, V. Lazar, 2011, Nature Reviews Clinical Oncology.

Integrated molecular portrait of non-small cell lung cancers

Pierre Validire, Philippe Dessen, Joakim Lundeberg, 2013, BMC Medical Genomics.

Identification of the Retinoic Acid – Inducible Gprc5a as a New Lung Tumor Suppressor Gene

R. Lotan, J. Lee, J. Fujimoto, 2022 .

Emerging circulating biomarkers in glioblastoma: promises and challenges

A. Idbaih, A. Alentorn, L. Lacroix, 2015, Expert review of molecular diagnostics.

Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas.

P. Varlet, I. Bièche, A. Kauffmann, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vemurafenib in pediatric patients with BRAFV600E mutated high‐grade gliomas

P. Varlet, A. Paci, B. Geoerger, 2014, Pediatric blood & cancer.

Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes

P. Varlet, N. Boddaert, S. Puget, 2015, Acta Neuropathologica.

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.

F. Bertucci, I. Bièche, F. André, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Whole exome sequencing of rare aggressive breast cancer histologies

Guangliang Yin, C. Lefebvre, M. Mathieu, 2016, Breast Cancer Research and Treatment.

Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas.

S. Filetti, J. Bidart, B. Caillou, 2001, Thyroid : official journal of the American Thyroid Association.

Na(+)/I(-) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues.

S. Filetti, J. Bidart, B. Caillou, 2001, European journal of endocrinology.

Expression of Na+/I- symporter and Pendred syndrome genes in trophoblast cells.

R. Frydman, V. Lazar, S. Filetti, 2000, The Journal of clinical endocrinology and metabolism.

Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes.

Thierry Pourcher, J. Bidart, B. Caillou, 2002, The Journal of clinical endocrinology and metabolism.

Co‐occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma

P. Varlet, N. Boddaert, D. Figarella-Branger, 2018, Brain pathology.

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR

L. Lacroix, B. Besse, J. Madic, 2018, Oncotarget.

Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer

L. Lacroix, B. Besse, E. Rouleau, 2017, PloS one.

Clinical, Imaging, Histopathological and Molecular Characterization of Anaplastic Ganglioglioma

B. Devaux, E. Dezamis, P. Varlet, 2016, Journal of neuropathology and experimental neurology.

Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.

S. Puget, C. Philippe, F. Andreiuolo, 2015, Neuro-oncology.

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

C. Lefebvre, F. André, M. Lacroix-Triki, 2016, PLoS medicine.

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome

C. Lázaro, G. Capellá, D. Planchard, 2020 .

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

I. Bièche, B. Job, J. Soria, 2020, JTO clinical and research reports.

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.

D. Planchard, S. Michiels, F. André, 2020, European journal of cancer.

Evaluation of a hybrid capture-based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes.

A. Stenzinger, M. Ligtenberg, F. Haller, 2020, The Journal of molecular diagnostics : JMD.

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients

Etienne Rouleau, Cécile Jovelet, Steven Blanchard, 2017, PloS one.

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

S. Broutin, J. Bidart, M. Schlumberger, 2012, The Journal of clinical endocrinology and metabolism.

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.

S. Broutin, J. Delahousse, A. Paci, 2018, European journal of cancer.

Massively parallel DNA sequencing from routinely processed cytological smears

J. Scoazec, N. Droin, P. Vielh, 2016, Cancer cytopathology.

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

J. Blay, D. Planchard, J. Mazières, 2020, Clinical Cancer Research.

Genomic Aberrations in Lung Adenocarcinoma in Never Smokers

B. Job, P. Dessen, A. Bernheim, 2010, PloS one.

ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome

O. Delattre, V. Combaret, B. Isidor, 2011, European Journal of Human Genetics.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

J-L Pretet, I. Bièche, J. Solassol, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC

Olivier Lantz, Laurence Zitvogel, Clotilde Théry, 2015, Oncoimmunology.

Attenuation of Soft-Tissue Sarcomas Resistance to the Cytotoxic Action of TNF-α by Restoring p53 Function

L. Vassilev, P. Terrier, S. Bonvalot, 2012, PloS one.

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

P. Validire, F. André, J. Adam, 2011, Clinical Cancer Research.

P5-01-07: Identification of SORBS2 as a Candidate Marker To Predict Metastatic Relapse in Breast Cancer.

F. André, P. Dessen, V. Lazar, 2011 .

S. Filetti, J. Bidart, D. Russo, 2014, Molecular and Cellular Endocrinology.

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib

J. Soria, L. Lacroix, B. Besse, 2016, Investigational New Drugs.

[Chromosomal rearrangements and fusion genes in carcinoma].

L. Lacroix, C. Massard, N. Auger, 2011, Bulletin du cancer.

Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer

D. Mallardo, P. Ascierto, E. Simeone, 2020, Nature Communications.

Cancer activation pathways of thymic epithelial tumors (TETs) by targeted gene expression analysis.

E. Fadel, B. Job, J. Scoazec, 2021 .

Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer

D. Planchard, J. Adam, J. Soria, 2016, Tumori.

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer

D. Planchard, L. Lacroix, B. Besse, 2019, Clinical Cancer Research.

Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines.

G. Tell, S. Filetti, F. Arturi, 2005, Endocrinology.

Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?

E. Baudin, J. Bidart, B. Caillou, 2011, Endocrine-related cancer.

Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma

D. Planchard, P. Cournède, J. Adam, 2020, European Radiology.

Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Non–Small-Cell Lung Cancer

N. Rosenfeld, D. Planchard, V. Plagnol, 2019, JCO precision oncology.

Tumorigenesis and Neoplastic Progression Follicular Thyroid Tumors with the PAX 8-PPAR 1 Rearrangement Display Characteristic Genetic Alterations

S. Michiels, P. Dessen, V. Lazar, 2005 .

Identification of genes expressed differentially in an in vitro human lung carcinogenesis model

R. Lotan, L. Lacroix, G. Feng, 2006, Cancer biology & therapy.

MET Genetic Abnormalities Unreliable for Patient Selection for Therapeutic Intervention in Oropharyngeal Squamous Cell Carcinoma

P. Vielh, L. Lacroix, S. Temam, 2014, PloS one.

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Jordi Remon, J. Pignon, D. Planchard, 2017, Lung cancer.

Regulation by human chorionic gonadotropin of sodium/iodide symporter gene expression in the JAr human choriocarcinoma cell line.

S. Filetti, J. Bidart, F. Arturi, 2002, Endocrinology.

Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion

P. Varlet, N. Boddaert, S. Puget, 2015, Acta Neuropathologica Communications.

Quantitative methylation analyses of resection margins predict local recurrences and disease-specific deaths in patients with head and neck squamous cell carcinomas

F. Janot, L. Lacroix, A. Aupérin, 2008, British Journal of Cancer.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Marie-Cécile Le Deley, Stefan Michiels, Caroline Even, 2017, Cancer discovery.

DNA FISH Diagnostic Assay on Cytological Samples of Thyroid Follicular Neoplasms †

B. Job, P. Dessen, C. Richon, 2020, Cancers.

Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion

P. Varlet, N. Boddaert, S. Puget, 2015, Acta neuropathologica communications.

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

J. Adam, J. Soria, M. Chiron, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

D. Planchard, F. André, J. Soria, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases

L. Xerri, A. Salomon, B. Esterni, 2013, BMC Cancer.

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

Thomas Bachelot, Florence Dalenc, Thomas Filleron, 2014, The Lancet. Oncology.

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

D. Planchard, F. André, J. Soria, 2016, Clinical Cancer Research.

First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.

J. Soria, L. Lacroix, E. Kempf, 2015, Clinical lung cancer.

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.

A. Eggermont, J. Adam, C. Robert, 2016, Cancer research.

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

B. Weisburd, F. McCormick, M. Holderfield, 2014, Cancer research.

Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies

S. Michiels, F. André, J. Lemonnier, 2019, Breast Cancer Research and Treatment.

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

D. Planchard, P. Saintigny, L. Lacroix, 2020, PloS one.

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer.

D. Planchard, V. Plagnol, J. Adam, 2020, JCO precision oncology.

Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma: New Insights in the Era of Molecular Pathology

P. Dartevelle, E. Fadel, T. le Chevalier, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis.

P. Chanson, P. Dessen, J. Bidart, 2010, Endocrine-related cancer.

A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer

J. Pignon, J. Adam, L. Lacroix, 2016, Oncotarget.

Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.

M. Schlumberger, C. Chougnet, S. Bardet, 2022, The New England journal of medicine.

Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma.

P. Validire, J. Soria, A. Bernheim, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?

M. Ducreux, J. Soria, L. Lacroix, 2013, OncoTargets and therapy.

Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups

F. André, P. Viens, L. Lacroix, 2012, Clinical Cancer Research.

Abstract 318: Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study

J. Thiery, E. Solary, A. Eggermont, 2019, Experimental and Molecular Therapeutics.

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

E. Solary, D. Planchard, A. Eggermont, 2020, npj Precision Oncology.

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

J. Pignon, D. Planchard, J. Adam, 2017, Oncotarget.

Gene expression signature discriminates sporadic from post-radiotherapy-induced thyroid tumors

J. Santini, J. Bidart, B. Caillou, 2010, Endocrine-related cancer.

Functional characterization of human thyroid tissue with immunohistochemistry.

S. Filetti, J. Bidart, B. Caillou, 2007, Thyroid : official journal of the American Thyroid Association.

Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.

D. Planchard, N. Chaput, J. Mazières, 2021, Lung cancer.

1025 Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening

F. André, E. Ruíz-García, J. Bidart, 2009 .

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

J. Pignon, D. Planchard, J. Soria, 2014, Lung cancer.

Abstract CT081: Pediatric precision medicine program in recurrent tumors: Results of the first 500 patients included in the European MAPPYACTS molecular profiling trial

O. Delattre, S. Michiels, B. Geoerger, 2019, Clinical Trials.

Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers

C. Genestie, J. Scoazec, A. Leary, 2020, Virchows Archiv.

Anaplastic Thyroid Carcinoma: An Update

E. Baudin, L. Lacroix, P. Blanchard, 2022, Cancers.

Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting

E. Solary, N. Droin, J. Bonastre, 2021, The European Journal of Health Economics.

Correction: Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study

Patricia Marino, Rajae Touzani, Lionel Perrier, 2018, European Journal of Human Genetics.

The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial

T. de Baère, J. Soria, S. Foulon, 2016, Genetics in Medicine.

BRAF and NRAS mutational status in clear cell sarcoma

B. Bui, P. Terrier, A. Cesne, 2005 .

Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.

L. Cerbone, F. Barlesi, L. Lacroix, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.

N. André, X. Paoletti, B. Geoerger, 2021, European journal of cancer.

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

E. Solary, T. de Baère, S. Michiels, 2018, European journal of cancer.

Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?

J. Soria, R. Sun, L. Lacroix, 2018, European Journal of Cancer.

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression

D. Planchard, C. Caramella, L. Lacroix, 2020 .

Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation

S. Filetti, D. Russo, G. Damante, 2014, Endocrine.

Regulation of iodide uptake and sodium/iodide symporter expression in the mcf-7 human breast cancer cell line.

S. Filetti, F. Arturi, D. Russo, 2005, The Journal of clinical endocrinology and metabolism.

P. Vielh, L. Lacroix, A. Aupérin, 2014, American journal of otolaryngology.

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.

Pierre Validire, Yudi Pawitan, Johan Hansson, 2015, Cancer research.

Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

N. Chaput, F. André, J. Soria, 2020, Nature Cancer.

Abstract 2401: Circulating cell-free tumor DNA (cfDNA) analysis of 50-genes by next-generation sequencing (NGS) in the prospective MOSCATO trial

A. Eggermont, T. Baère, F. André, 2015 .

MET receptor amplification drives resistance to Anti-EGFR therapies

J. Soria, L. Lacroix, E. Castañón, 2019, Journal of Immunotherapy and Precision Oncology.

Differential expression of galectin‐3 in medullary thyroid carcinoma and C‐cell hyperplasia

E. Baudin, J. Bidart, B. Caillou, 2002, Clinical endocrinology.

Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

O. Bernard, J. Soria, L. Lacroix, 2023, American journal of hematology.

Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.

A. Italiano, F. Barlesi, L. Lacroix, 2023, JCO precision oncology.

Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study

D. Planchard, S. Michiels, F. André, 2019, Annals of Oncology.

Detection of additional occult malignancy though profiling of ctDNA in late-stage cancer patients.

L. Lacroix, Y. Loriot, A. Hollebecque, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients.

D. Planchard, S. Michiels, F. Barlesi, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular screening for a personalized treatment approach in advanced adrenocortical cancer.

E. Baudin, F. Pattou, Jacques Young, 2013, The Journal of clinical endocrinology and metabolism.

Using methylation signatures on cell-free DNA for early cancer detection: A new era in liquid biopsy?

S. Delaloge, L. Lacroix, E. Barranger, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract 2250: STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance

J. Pignon, D. Planchard, J. Soria, 2016 .

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

E. Solary, O. Mir, T. de Baère, 2018, European journal of cancer.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers

E. Solary, T. de Baère, S. Michiels, 2018, Oncotarget.

Abstract 36: The OncoNetwork Consortium: A European Collaborative Research study on the development of an Ion AmpliSeq gene panel targeting hot spots in colon and lung cancers.

B. Tops, A. Scarpa, I. Cree, 2013 .

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

D. Planchard, S. Michiels, F. André, 2020, JTO clinical and research reports.

Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations.

C. Lefebvre, F. André, Yu Fu, 2016, Cancer research.

Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing

J. Scoazec, O. Bawa, L. Lacroix, 2020, Scientific Reports.

Activation of Protein Kinase C by Phorbol 12-Myristate 13-Acetate suppresses the growth of lung cancer cells through KLF6 induction

R. Lotan, D. Lotan, L. Lacroix, 2009, Cancer biology & therapy.

ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report.

J. Pignon, D. Planchard, J. Soria, 2012 .

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

N. Rosenfeld, D. Planchard, V. Plagnol, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

J. Thiery, E. Solary, D. Planchard, 2019, Clinical Cancer Research.

EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.

E. Fadel, T. le Chevalier, M. Ghigna, 2017, Pathology, research and practice.

Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01).

I. Bièche, M. Mathieu, F. André, 2013 .

MA21.07 Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF+ Non-Small Cell Lung Cancer

D. Planchard, J. Mazières, P. Saintigny, 2019, Journal of Thoracic Oncology.

Sodium iodide symporter and pendrin expression in human thyroid tissues.

J. Bidart, B. Caillou, M. Schlumberger, 2001, Thyroid : official journal of the American Thyroid Association.

An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.

D. Planchard, V. Plagnol, J. Adam, 2018 .

Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel

H. Feilotter, B. Tops, R. Franco, 2014 .

EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts

P. Opolon, B. Geoerger, G. Vassal, 2008, International journal of cancer.

HEX, PAX‐8 and TTF‐1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism

S. Michiels, S. Filetti, J. Bidart, 2006, Clinical endocrinology.

Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium

B. Tops, P. Laurent-Puig, A. Scarpa, 2015, BMC Cancer.

Cost Of Genome Analysis: The Sanger Sequencing Method.

J. Merlio, P. Marino, L. Lacroix, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Detection of myeloid malignancies through cfDNA profiling in patients with advanced stage cancer

L. Lacroix, Y. Loriot, A. Hollebecque, 2022, European Journal of Cancer.

The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy

F. André, J. Soria, C. Robert, 2012, Molecular oncology.

Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer

F. André, C. Balleyguier, S. Delaloge, 2009, Cancer.

Atypical teratoid rhabdoid tumor mimicking beta-catenin-positive nodular medulloblastoma

P. Varlet, N. Boddaert, S. Puget, 2011, Acta Neuropathologica.

Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study.

P. Petrow, S. Faivre, L. Lacroix, 2010 .

Phase I/II study of the association of sorafenib and temozolomide (extended schedule) in patients with metastatic melanoma: A new clinical response profile with massive tumor necroses.

L. Zitvogel, V. Lazar, J. Soria, 2009, Journal of Clinical Oncology.

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer

C. Genestie, A. Leary, L. Lacroix, 2023, International journal of molecular sciences.

Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study

O. Delattre, S. Michiels, X. Paoletti, 2017 .

Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.

R. Lotan, J. Fujimoto, J. Clifford, 2007, Journal of the National Cancer Institute.

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

M. Lacroix-Triki, B. Job, S. Christodoulidis, 2023, Nature Medicine.

Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC).

V. Plagnol, J. Soria, L. Lacroix, 2017 .

Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304)

I. Bièche, I. Soubeyran, F. André, 2017 .

Molecular screening for cancer treatment optimization (MOSCATO 01) in pediatric patients: First feasibility results of a prospective molecular stratification trial.

P. Varlet, T. Baère, S. Puget, 2014 .

3025 Prognostic value of PDL1 expression in stage III Non-Small Cell Lung Cancer (NSCLC) treated by chemo-radiotherapy (CRT)

J. Pignon, D. Planchard, J. Adam, 2015 .

SO-4 Impact of molecular profiling on survival in patients with advanced biliary tract cancers

M. Ducreux, V. Boige, L. Lacroix, 2023, Annals of Oncology.